Mentor Siltex® Contour Profile Gel Mammary Prosthesis Clinical Trial

Breast Reconstruction Clinical Trial

— CPG  

Official title:

Study of the Safety and Effectiveness of Mentor Siltex® Contour Profile Gel Mammary Prostheses in Patients Who Are Undergoing Primary Breast Augmentation,Primary Breast Reconstruction or Revision

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00812097
• Other study ID #: A105-0601-4
• Status: Completed
• Phase: Phase 3
• First received: December 17, 2008
• Last updated: January 22, 2015
• Start date: February 2002
• Est. completion date: October 2014

Study information

• Verified date: January 2015
• Source: Mentor Worldwide, LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The Contour Profile Gel Study is designed to demonstrate safety and effectiveness of Mentor's Mammary Prostheses in women who are undergoing primary augmentation, primary reconstruction, or revision. Safety information on the rate of capsular contracture, rupture, and infection will be collected, and used to help determine device safety.

Approximately 1000 patients at approximately 60 medical centers across the United States were enrolled in this research study. These patients were implanted with silicone breast prostheses and will be monitored for 10 years to collect information on risks associated with the implant surgery as well as changes in the way these patients feel about themselves.

Description:

Silicone gel-filled breast implants were introduced in the early sixties and were in wide-scale distribution by the time the Medical Device Amendments to the Food Drug and Cosmetic Act was passed in 1976. In 1983, gel-filled breast implants were designated as Class III devices requiring premarket approval. In May 1990, the Food and Drug Administration (FDA) published a proposed request (515(b)) for Premarket Approval Applications (PMA) and in April 1991 published the final request. This final publication put manufacturers of gel-filled breast implants on notice that for continued marketing of gel-filled breast implants, a PMA was due to FDA in 90 days from the final publication date.

A premarket approval (PMA) for the Mentor gel-filled breast implants was filed with the FDA in July 1991. At the FDA General and Plastic Surgery Advisory Committee meeting in November 1991, the committee recommended the submission of additional information to establish the safety and effectiveness of gel-filled breast implants.

In January 1992, the FDA Commissioner announced a voluntary moratorium of the sale of gel-filled breast implants to allow the advisory panel time to assess additional information. In April 1992, the moratorium was lifted but only for reconstruction and revision patients. Every patient implanted had to be part of an adjunct study, and had to be offered participation in a registry of gel-filled breast implant patients. In order to be implanted with gel-filled implants for augmentation, women had to be enrolled in a core clinical study.

In September of 2000 the Core Gel study began, leading the way to the November 2006 FDA approval of the Core Gel implant or Memory Gel breast implant.

The objective of the Contour Profile Gel Study, which started in 2002 is to determine the safety and effectiveness of the Silicone Contour Profile Gel Mammary Prostheses in women who are undergoing primary breast augmentation, primary breast reconstruction, or revision. In the duration of this study patients are required to have follow-up visits 10 weeks post-surgery and every year after surgery through the 10th year of completion. Additionally, out of the approximately 1000 patients enrolled in the CPG study, 400 have been randomly selected to have MRI scans at their 1,2,4,6,8,and 10 year post-surgery visits. Protocol changes now require all patients in this study to have MRI scans at years 6, 8, and 10.

In June of 2013 the FDA approved MENTOR® MemoryShape™ Breast Implants (CPG Style 321 Medium Height, Moderate Profile) for the following indications:

• Breast Augmentation for women at least 22 years old.

• Breast Reconstruction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 955
• Est. completion date: October 2014
• Est. primary completion date: October 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject is genetic female, 18 years of age or older

• A candidate for:

• Primary breast augmentation (general breast enlargement)

• Primary breast reconstruction (for trauma, loss of breast tissue due to mastectomy, malignancy, contralateral post-reconstruction symmetry, congenital deformity, including asymmetry)

• Revision surgery (previous augmentation or reconstruction with silicone-filled or saline-filled implants)

• Signs the Informed Consent

• Agrees to return device to Mentor if explant necessary

• Agrees to comply with follow-up procedures, including returning for all follow-up visits

Exclusion Criteria:

• Subject is pregnant

• Has nursed a child within three months of study enrollment

• Been implanted with any silicone implant other than breast implants (e.g. silicone artificial joints or facial implants)

• Confirmed diagnosis of the following rheumatic diseases or syndromes: SLE, Sjogren's syndrome, scleroderma, polymyositis, or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, any other inflammatory arthritis, fibromyalgia, or chronic fatigue syndrome

• Currently has a condition that could compromise or complicate wound healing (except reconstruction subjects)

• Subject in Augmentation cohort and has diagnosis of active cancer of any type. (Exception is low-grade non-metastasizing skin cancer)

• Infection or abscess anywhere in the body

• Demonstrates tissue characteristics which are clinically incompatible with implant (e.g. tissue damage resulting from radiation, inadequate tissue, or compromised vascularity)

• Possesses any condition, or is under treatment for any condition which, in the opinion of the investigator and/or consulting physicians(s), may constitute an unwarranted surgical risk

• Anatomic or physiologic abnormality which could lead to significant postoperative adverse events

• Demonstrates characteristics that are unrealistic/unreasonable with the risks involved with the surgical procedure

• Premalignant breast disease without a subcutaneous mastectomy

• Untreated or inappropriately treated breast malignancy, without mastectomy

• Are HIV positive

• Work for Mentor or the study doctor or are directly-related to anyone that works for Mentor or the study doctor

• Implanted metal or metal devices, history of claustrophobia or other condition that would make a MRI scan prohibitive

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Augmentation
• Breast Reconstruction
• Breast Revision

Intervention

Device:
• Mentor Siltex® Contour Profile Gel Mammary Prosthesis
The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The thicker consistency provides a higher resistance to flow. The gel is made from the same materials as Mentor's standard silicone gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant. These marks help the physician orient the implant and ensure proper placement during implantation. CPG is available in sizes 120 cc-775 cc and 5 styles with various projection and height options.

Locations

Country	Name	City	State
United States	Mentor Worldwide, LLC	Santa Barbara	California

Sponsors (1)

Lead Sponsor	Collaborator
Mentor Worldwide, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety will be determined by the incidence, severity, method of resolution, and duration for all adverse events on a per implant and a per patient basis.		10 years	Yes
Primary	Effectiveness will be determined by the changes in chest circumference and bra and cup size.		10 years	No
Secondary	Effectiveness will also be determined by changes in Quality of Life questionnaire results.		10 years	No

External Links

•   Link